Jim Cramer Discusses Kura Oncology as a Speculative Bet

Group 1 - Kura Oncology, Inc. is focused on developing targeted cancer therapies for genetically defined leukemias and solid tumors, with several drug candidates in clinical development [2] - The company received FDA approval for KOMZIFTI, a once-daily oral targeted therapy for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia [2] - Early trial results for KOMZIFTI combined with venetoclax and azacitidine showed overall response rates of 65% and 41% in relapsed/refractory NPM1-m and KMT2A-r AML, with higher rates in venetoclax-naïve patients [2] Group 2 - Kura Oncology is noted for its milestone payment of $135 million related to the U.S. commercial sale of KOMZIFTI, indicating significant commercial potential [1] - The company is viewed as a speculative investment in the cancer treatment space, with larger competitors like Johnson & Johnson and Merck being ahead in the market [1] - Despite the potential of Kura Oncology, certain AI stocks are suggested to offer greater upside potential and less downside risk [2]